CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals, a new fully integrated drug development company offering an innovative alternative model for drug development commercializiation, today announced the appointment of Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer and Constantine Chinoporos, as Chief Business Officer. Both will work with senior leadership at the company to identify and partner with academic, biotechnology and biopharmaceutical groups to acquire clinical assets at various stages of their development and bring them to market.
Dr. Arroyo joins Boston Pharmaceuticals from Pfizer, where he was Senior Vice President and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics, responsible for clinical pharmacology in the areas of Neuroscience, Pain, Rare Diseases, Cardiovascular and Metabolism. He was previously Therapeutic Area Head, Neuroscience Research Unit at Bristol-Myers Squibb, and Therapeutic Area Head for Neurosciences at Eisai Dr. Arroyo was Instructor in Neurology at the Johns Hopkins Hospital and helped set up and ran the epilepsy programs at the Medical College of Wisconsin and Hospital Clinic of Barcelona, Spain. Dr. Arroyo received his medical degree from the Autonomous University of Madrid and his Ph.D. from the University of Barcelona, Spain.
Mr. Chinoporos was formally Vice President of Global Licensing and Business Development at Sanofi where he was responsible for the global licensing activities. Previously he was Vice President of Corporate Development at Genzyme and Alliance Manager of Primary Care Product Group at E. Lilly and Company. Mr. Chinoporos received his B.A. and MBA from Cornell University.
Announcing these appointments, Christopher Viehbacher, Executive Chairman, Boston Pharmaceuticals stated “Dr. Arroyo brings to Boston Pharmaceuticals a deep and broad experience in the clinical development of programs across multiple therapeutic areas and a successful track record in the development of launched products. He has a highly patient-focused approach to clinical development and the regulatory experience to successfully drive programs through to commercialization. Dr. Arroyo’s depth of experience and extensive network of health industry experts will be critical to delivering our alternative virtual development model.”
“I am excited to be part of Boston Pharmaceuticals and to join the team creating a substantial portfolio of clinical programs across important disease states to bring new medicines to patients” said Dr. Arroyo. “I look forward to partnering with biotechnology and biopharmaceutical companies in identifying and further developing potential new medicines.”
Mr. Chinoporos, Chief Business Officer, brings to Boston Pharmaceuticals his extensive experience in business development and licensing across a broad array of transaction structures. “Mr. Chinoporos has been extensively involved in both biotech and pharma licensing of successful programs across development and commercial phases and brings critical insights into new product opportunities” said Dr. Rob Armstrong, CEO, Boston Pharmaceuticals. “We welcome him to our team and look forward to his transaction and strategic insights as we continue building our portfolio.”
“Boston Pharmaceuticals is intensely focused on efficient clinical development of new medicines and I look forward to helping build an extensive portfolio of new and novel products” said Mr. Chinoporos. “This is an opportunity to leverage my extensive network of industry partners in identifying great licensing opportunities that can ultimately benefit patients.”
About Boston Pharmaceuticals
Boston Pharmaceuticals offers a novel approach to drug development and commercialization, providing new strategic partnership options to academic and biopharmaceutical groups. With a unique team of highly experienced professionals and a significant long-term base of capital, we seek to develop new medicines from early development to proof of concept and beyond. Our mission is to provide novel strategic alternatives to companies and academics wishing to further de-risk and unlock the value of life improving medicines. We combine our team’s extensive clinical and business experience and a long-term capital base to efficiently develop programs to key clinical milestones for partnering and commercialization.